Neurocrine Biosciences, Inc. (NBIX) Q1 2008 Earnings Results

Neurocrine Biosciences Misses on EPS, Stock Down 2.51%

The earnings report indicates that Neurocrine Biosciences is still in a development phase, as evidenced by the lack of revenue figures and guidance. The stock reaction, down 2.51%, suggests that investors are concerned about the company's financial trajectory and the absence of concrete updates. This could lead to increased scrutiny in the coming quarters as the market awaits more information on their product pipeline and financial health.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.55	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook without providing specific financial guidance. They emphasized their commitment to advancing their pipeline.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The focus remains on ongoing research and development efforts.

Neurocrine Biosciences Misses on EPS, Stock Down 2.51%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS, Stock Down 2.51%

Key numbers

Management commentary